FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 349:1307-1309 October 2, 2003 Number 14 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Moses, J. W. PubMed Citation

Sirolimus (rapamycin), an inhibitor of in-stent restenosis in the coronary arteries, is having a substantial effect on the care of patients with coronary artery disease, was discovered in a soil sample from Easter Island (known locally as Rapa Nui). A naturally occurring product that is isolated from Streptomyces hygroscopicus, sirolimus is an extremely lipophilic (hydrophobic) macrolide that was initially developed as an antifungal agent on the basis of its ability to inhibit the growth of yeast. However, sirolimus was quickly observed to have potent immunosuppressive activity in mammals, which put a halt to its development as an antibiotic.

In 1988, . . . [Full Text of this Article]

Source Information

From the Department of Physiology and Cellular Biophysics, Center for Molecular Cardiology, Columbia University College of Physicians and Surgeons, New York.

This article has been cited by other articles:

• Shroff, R., Roebuck, D. J., Gordon, I., Davies, R., Stephens, S., Marks, S., Chan, M., Barkovics, M., McLaren, C. A., Shah, V., Dillon, M. J., Tullus, K. (2006). Angioplasty for Renovascular Hypertension in Children: 20-Year Experience. Pediatrics 118: 268-275 [Abstract] [Full Text]  
• Wessely, R., Schomig, A., Kastrati, A. (2006). Sirolimus and Paclitaxel on Polymer-Based Drug-Eluting Stents: Similar But Different. J Am Coll Cardiol 47: 708-714 [Abstract] [Full Text]  
• Kristof, A. S., Pacheco-Rodriguez, G., Schremmer, B., Moss, J. (2005). LY303511 (2-Piperazinyl-8-phenyl-4H-1-benzopyran-4-one) Acts via Phosphatidylinositol 3-Kinase-Independent Pathways to Inhibit Cell Proliferation via Mammalian Target of Rapamycin (mTOR)- and Non-mTOR-Dependent Mechanisms. J. Pharmacol. Exp. Ther. 314: 1134-1143 [Abstract] [Full Text]  
• Sakakibara, K., Liu, B., Hollenbeck, S., Kent, K. C. (2005). Rapamycin inhibits fibronectin-induced migration of the human arterial smooth muscle line (E47) through the mammalian target of rapamycin. Am. J. Physiol. Heart Circ. Physiol. 288: H2861-H2868 [Abstract] [Full Text]  
• Thomas, M R (2005). Brachytherapy: here today, gone tomorrow?. Heart 91: iii32-iii34 [Full Text]  
• Fukuda, D., Sata, M., Tanaka, K., Nagai, R. (2005). Potent Inhibitory Effect of Sirolimus on Circulating Vascular Progenitor Cells. Circulation 111: 926-931 [Abstract] [Full Text]  
• Schwartz, R. S., Chronos, N. A., Virmani, R. (2004). Preclinical restenosis models and drug-eluting stents: Still important, still much to learn. J Am Coll Cardiol 44: 1373-1385 [Abstract] [Full Text]  
• Hay, N., Sonenberg, N. (2004). Upstream and downstream of mTOR. Genes Dev. 18: 1926-1945 [Abstract] [Full Text]  
• Andres, V. (2004). Control of vascular cell proliferation and migration by cyclin-dependent kinase signalling: new perspectives and therapeutic potential. Cardiovasc Res 63: 11-21 [Abstract] [Full Text]  
• Levin, A. D., Vukmirovic, N., Hwang, C.-W., Edelman, E. R. (2004). Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel. Proc. Natl. Acad. Sci. USA 101: 9463-9467 [Abstract] [Full Text]  
• Antman, E. M., Van de Werf, F. (2004). Pharmacoinvasive Therapy: The Future of Treatment for ST-Elevation Myocardial Infarction. Circulation 109: 2480-2486 [Full Text]  
• Lindemann, S. W., Yost, C. C., Denis, M. M., McIntyre, T. M., Weyrich, A. S., Zimmerman, G. A. (2004). Neutrophils alter the inflammatory milieu by signal-dependent translation of constitutive messenger RNAs. Proc. Natl. Acad. Sci. USA 101: 7076-7081 [Abstract] [Full Text]  
• (2004). MORE POSITIVE NEWS ABOUT SIROLIMUS-ELUTING STENTS. Journal Watch Cardiology 2004: 2-2 [Full Text]  
• (2003). More Positive News About Sirolimus-Eluting Stents from the U.S.. Journal Watch Cardiology 2003: 1-1 [Full Text]  
• (2003). Will Sirolimus-Eluting Stents Consign Bare Metal to History?. JWatch General 2003: 1-1 [Full Text]